Bridging therapies may be considered but can be costly and risky
This change in appearance after weight loss with GLP-1 agonist medications is often referred to as GLP-1 face
However, theyre not completely risk-free
Stay informed, explore current alternatives, and connect with Klinic to ensure you're prepared when potential treatments like Retatrutide become available
Why This Matters More For Women in Mid-Life Women in menopause and beyond face a specific metabolic landscape: declining estrogen, increasing insulin resistance, accelerating visceral fat accumulation, and anabolic resistance
The Bottom Line Foundayo (orforglipron) is a real, FDA-approved oral GLP-1 medication that eliminates the injection and fasting barriers that have kept many eligible patients from starting GLP-1 therapy